PharmTech Weekly Roundup—June 19, 2026

Themes that emerged this week on PharmTech.com include industry pressures to do more with greater precision—whether that means tighter quality controls, cleaner processes, or smarter use of technology. Artificial intelligence (AI) is reshaping operations across the industry, but its governance in regulated environments remains an open, urgent question. And domestic investment in US manufacturing capacity is accelerating, with workforce development emerging as a critical bottleneck.

In news this week, the FDA approved the first generic version of Xofluza (baloxavir marboxil) tablets for the treatment and prevention of acute uncomplicated influenza in patients 5 years of age and older— the approval may signal the arrival of complex antivirals entering the generics pipeline and opens new manufacturing competition ahead of the 2026–2027 flu season.

The FDA granted priority review to AstraZeneca's supplemental biologics license application forravulizumab—a treatment for the rare inflammatory kidney disease, immunoglobulin A nephropathy. If approved, the drug would be the first C5 complement inhibitor for this indication, where roughly half of high-risk patients progress to kidney failure within a decade.

Nitrosamines continue to impact drug manufacturing. A voluntary recall issued in June of duloxetine lots because of elevated N-nitroso-duloxetine levels is the latest in a recurring pattern of nitrosamine contamination in generic drugs. This may indicate that ongoing synthetic route risk assessments, not just finished-product testing, are essential for generic-drug manufacturers.

Industry experts tackled a variety of development and manufacturing topics on PharmTech.com this week.

Consultant, Ajoy Koppolu, explained that to successfully manufacture peptide therapies in prefilled syringes for high-speed autoinjectors, a coordinated lifecycle approach is the best approach. This approach integrates formulation design, Cpk-driven quality control, and factory acceptance testing to ensure consistent, compliant dose delivery.

Early formulation and manufacturing decisions drive up to 80% of a drug's environmental impact — and solvent-free, fusion-based alternatives to traditional spray-dried dispersion processes offer a path to reducing both operational complexity and environmental burden simultaneously, according to Elizabeth Hickman, CEO of AustinPX.

USP’s Michael Levy detailed how the organization is advancing machine-readable, digitally structured quality standards that integrate directly into laboratory workflows — enabling pharmaceutical manufacturers to modernize quality assurance without sacrificing data integrity or regulatory confidence.

The incorporation of AI into pharmaceutical development and manufacturing continues to advance in the industry, but not always successfully. An FDA warning letter to a manufacturer that relied on an AI agent to write procedures — without qualified human oversight — highlights that the real governance challenge of AI in pharma is not content accuracy but ensuring that quality system controls keep pace with the speed at which AI generates change. Brian Drapeau, founder, GxPFrame, asks Is Compliant AI in Pharma Even Possible?

Lucinda Smith, chief safety product officer at ArisGlobal, suggests that AI-enabled end-to-end case processing in pharmacovigilance could reduce adverse event reporting timelines from days to hours — making the current seven-day SUSAR requirement not just achievable but obsolete, provided robust governance frameworks are in place.

Karianne Gelinas, vice president of talent strategies at the Lehigh Valley Economic Development Corporation, provided insight on Eli Lilly’s selection of Pennsylvania's Lehigh Valley for its new $3.5 billion injectable medicine facility. The region had spent years strategically cultivating a pharmaceutical manufacturing workforce — including apprenticeship programs and academic partnerships — capable of filling more than 850 technical roles. The Lehigh Valley Economic Development Corporation is deploying a multi-pronged talent strategy — spanning K–12 STEM pipelines, pre-apprenticeships, and regional university engagement — to supply the skilled workforce Lilly's new facility will require.

In more business development news, according to Kristin Ciriello Pothier at KPMG, biopharma dealmakers have shifted from transaction volume to strategic precision — with oncology, GLP-1s, and the regional manufacturing constraints of cell and gene therapies now central to how deals are structured and valued. When acquiring platform technologies, Pothier says the strength of clinical and cross-indication bridging data is the single most important factor in maximizing deal value — with supply chain resilience and regional manufacturing capability increasingly scrutinized in due diligence.

When it comes to rare disease development, David O’Connell of PCI Pharma Services, says that with approximately 35% of global R&D pipelines now targeting rare diseases, optimizing impact in this space requires precision-first CDMO partnerships capable of managing highly potent molecules, small-batch production, and global multi-jurisdictional distribution from a single integrated framework.

Quality pressure, AI governance, and domestic manufacturing investment are currently defining the industry. Thank you for watching.